REGENXBIO Inc.

REGENXBIO Inc.

World Rank (Aug-2026)
10863
Market Cap (Aug-2026)
0.711 Billion USD
Market Cap (Mar-08-2026)
0.438 Billion USD
World Rank (Jan-05-2024)
10,026
Market Cap (Jan-05-2024)
0.765 Billion USD
World Rank (Jul-30-2023)
9,791
Market Cap (Jul-30-2023)
0.818 Billion USD
World Rank (Jan-07-2022)
8,285
Market Cap (Jan-07-2022)
1.248 Billion USD
World Rank (Jan-01-2021)
5,995
Market Cap (Jan-01-2021)
1.697 Billion USD
Headquarters Country
USA
Top Technology Companies in USA
Top Healthcare Companies in USA
Nasdaq / NYSE Code
RGNX
Employee Count
372
Employee Count as of Date
As on 2021
Headquarters City/State
Maryland
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
170 Million USD
Annual Operating Income in USD
-161 Million USD
Annual Net Income in USD
-194 Million USD
Annual Results for Period Ending
For year ending December-2025
Total Assets in USD
453 Million USD
Total Liabilities in USD
350 Million USD
Total Equity in USD
103 Million USD
Balance Sheet for Period Ending
As of December-2025
Business Sector
Healthcare
Biotechnology
Technology
HealthCare Products
Company Website
REGENXBIO INC
Yahoo
Yahoo @ Nasdaq
Company Profile
REGENXBIO is a Clinical Stage Biotechnology company. The company currently developing gene therapy product candidates for the treatment of retinal, metabolic and neurodegenerative diseases and provide long lasting effects, potentially significantly altering the course of disease and delivering improved patient outcomes. The headquarters is in USA.
IPO Year
2015
Stock Exchange
Nasdaq
Frankfurt
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share